

(FDA, Approval)



Merck's CAPVAXIVE gets FDA approval for an expanded indication that includes those aged 12-17 years with an increased pneumococcal disease risk

(FDA, Approval)



AbbVie's Allergan Aesthetics receives FDA approval for SKINVIVE by JUVÉDERM to reduce neck lines in adults over the age of 21

(FDA, Approval)



FDA approves GSK and Spero Therapeutics' UTEBZI for the treatment of cUTIs, including pyelonephritis, in adults with limited or no alternative oral options

(EU, Approval)



EC gives centralized marketing authorization to CinnaGen's ZANDORIAH, a biosimilar for the treatment of osteoporosis in adults



(MHLW, Approval)



Japan's MHLW approves Sanofi's SARCLISA SC formulation, in combination with SOC regimens, for the treatment of multiple myeloma

(FDA, Orphan Drug)



Island Pharmaceutical's Galidesivir gets Orphan Drug Designation from the FDA for the post-exposure prophylaxis of Marburg virus disease

(EU, Orphan Drug)



EC grants Orphan Drug Designation to Zai Lab's zoci for the treatment of pulmonary neuroendocrine carcinomas

(Acquisition)



Bayer acquires Perfuse Therapeutics for USD 300M, now holding full rights to PER-001, an intravitreal implant, strengthening its ophthalmology expertise





UCB acquires Candid Therapeutics for USD 2.2B, expanding next-generation biologics capabilities and thereby strengthening its immunology position

(Acquisition)



Eli Lilly acquires 4E Therapeutics, including the company's lead compound 4ET1103, which is under development for pain

(Acquisition)



Jazz Pharmaceuticals and AbCellera collaborates for preclinical research and licensing to discover and develop next-generation TCE multispecific antibodies

(Collaboration)



Eli Lilly collaborates with BioArctic for USD 30M to research a new neurodegeneration treatment that combines BrainTransporter technology with an undisclosed drug candidate

(Collaboration)

